Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients
Liver International2016Vol. 36(12), pp. 1755–1764
Citations Over TimeTop 1% of 2016 papers
Tung‐Hung Su, Tsung‐Hui Hu, Chi‐Yi Chen, Yi‐Hsiang Huang, Wan‐Long Chuang, Chun‐Che Lin, Chia‐Chi Wang, Wei‐Wen Su, Ming‐Yao Chen, Cheng‐Yuan Peng, Rong‐Nan Chien, Yi‐Wen Huang, Horng‐Yuan Wang, Chih‐Lin Lin, Sheng‐Shun Yang, Tsung‐Ming Chen, Lein‐Ray Mo, Shih‐Jer Hsu, Kuo‐Chih Tseng, Tsai‐Yuan Hsieh, Fat‐Moon Suk, Chi‐Tan Hu, Ming‐Jong Bair, Cheng‐Chao Liang, Yung‐Chao Lei, Tai‐Chung Tseng, Chi‐Ling Chen, Jia‐Horng Kao
Abstract
Four-year entecavir therapy significantly reduces the risk of HCC, cirrhotic events and mortality in patients with CHB-related cirrhosis.
Related Papers
- → Clinical utility of entecavir for chronic hepatitis B in Chinese patients(2013)13 cited
- → Is tenofovir and entecavir combination therapy still the optimal treatment for chronic hepatitis B patients with prior suboptimal response?(2020)3 cited
- → Efficacy and safety of long-term therapy with Entecavir (ETV) or Tenofovir (TDF) in patients with HBV-related cirrhosis(2014)1 cited
- → Research progress of entecavir treatment for chronic hepatitis B special patients(2013)
- → Sa1624 SWITCHING TO TENOFOVIR (TAF) THERAPY VS. CONTINUING WITH ENTECAVIR (ETV) THERAPY IN ENTECAVIR-TREATED CHRONIC HEPATITIS B PATIENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS(2024)